Industry Experts

Bruno Figueroa, Ph.D. is the Global Head of Genomic Medicine Unit CMC at  Sanofi, where he has spent over five years driving innovation in cell and gene therapy  CMC development. He built Sanofi's Genomic Medicine CMC organization, establishing  industry-leading capabilities in AAV gene therapy and non-viral lipid nanoparticle (LNP)  platforms.  
A leader with over two decades of biologics development experience, Bruno is deeply  passionate about bringing transformative cell and gene therapies to patients with high  unmet medical needs. He is recognized for his technical expertise in drug substance  process development, as well as CMC development strategy, technology transfer,  clinical GMP manufacturing and regulatory strategy. His leadership philosophy  emphasizes scientific excellence, innovation, diversity, and empowering high performing global teams to achieve operational excellence.

Prior to Sanofi, Bruno held progressive leadership positions in bioprocess development  at Johnson & Johnson's Centocor, Tanox (acquired by Genentech), and Pfizer. He  received his Ph.D. in Chemical Engineering from The Johns Hopkins University and his  B.S. in Chemical Engineering from The University of Tulsa. Bruno is a member of the  American Society of Gene & Cell Therapy and has authored numerous peer-reviewed  publications and patents in the field.